Lancet neurology
-
Spinal cord injury is currently incurable and treatment is limited to minimising secondary complications and maximising residual function by rehabilitation. Improved understanding of the pathophysiology of spinal cord injury and the factors that prevent nerve and tissue repair has fuelled a move towards more ambitious experimental treatments aimed at promoting neuroprotection, axonal regeneration, and neuroplasticity. ⋯ However, in view of recent advances in spinal cord injury research and demand from patients, clinicians, and the scientific community to push promising experimental treatments to the clinic, momentum and optimism exist for the translation of candidate experimental treatments to clinical spinal cord injury. The ability to rescue, reactivate, and rewire spinal systems to restore function after spinal cord injury might soon be within reach.
-
Elizabeth Bradbury is a Medical Research Council Senior Fellow at King's College London (London, UK). She trained as a neuroscientist at the Institute of Psychiatry and St Thomas' Hospital in London before becoming a group leader at King's in 2003. Her research focuses on understanding processes of injury and repair and developing therapies to restore function following CNS trauma, with a particular interest in glial scarring, extracellular matrix modification, and neuroplasticity after spinal cord injury.
-
Randomized Controlled Trial Multicenter Study
Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial.
The primary outcome results for the SPS3 trial suggested that a lower systolic target blood pressure (<130 mm Hg) might be beneficial for reducing the risk of recurrent stroke compared with a higher target (130-149 mm Hg), but that the addition of clopidogrel to aspirin was not beneficial compared with aspirin plus placebo. In this prespecified secondary outcome analysis of the SPS3 trial, we aimed to assess whether blood pressure reduction and dual antiplatelet treatment affect changes in cognitive function over time in patients with cerebral small vessel disease. ⋯ US National Institute of Neurological Disorders and Stroke.
-
Multicenter Study Observational Study
Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
Although the association between cytosine-adenine-guanine (CAG) repeat length and age at onset of Huntington's disease is well known, improved prediction of onset would be advantageous for clinical trial design and prognostic counselling. We compared various measures for tracking progression and predicting conversion to manifest Huntington's disease. ⋯ US National Institutes of Health, US National Institute of Neurological Disorders and Stroke, and CHDI Foundation.